Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2005-05-03
2005-05-03
Gitomer, Ralph (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S030000, C435S032000, C435S261000
Reexamination Certificate
active
06887680
ABSTRACT:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. With respect to the culturing of malignant cells, for example, it is believed (without any intention of being bound by the theory) that by maintaining the malignant cells within a multicellular particulate of the originating tissue, growth of the malignant cells themselves is facilitated versus the overgrowth of fibroblasts or other cells which tends to occur when suspended tumor cells are grown in culture. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. Growth of cells is monitored to ascertain the time to initiate the assay and to determine the growth rate of the cultured cells; sequence and timing of drug addition is also monitored and optimized. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.
REFERENCES:
patent: 4423145 (1983-12-01), Stampfer et al.
patent: 4559299 (1985-12-01), Rotman
patent: 4668618 (1987-05-01), Thornthwaite
patent: 4816395 (1989-03-01), Hancock et al.
patent: 4937187 (1990-06-01), Rotman
patent: 4996145 (1991-02-01), Weisenthal
patent: 5242806 (1993-09-01), Yen-Maguire et al.
patent: 5270172 (1993-12-01), Morgan
patent: 5403574 (1995-04-01), Piwnica-Worms
patent: 5443950 (1995-08-01), Naughton et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5705270 (1998-01-01), Soon-Shiong et al.
patent: 5728541 (1998-03-01), Kornblith
patent: 5789158 (1998-08-01), Knowles et al.
patent: 5874218 (1999-02-01), Drolet et al.
patent: 5888765 (1999-03-01), Patterson et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5972639 (1999-10-01), Parandoosh
patent: 6008007 (1999-12-01), Fruehauf et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6111092 (2000-08-01), Williamson
patent: 6261795 (2001-07-01), Fruehauf et al.
patent: 6303324 (2001-10-01), Fruehauf
patent: 6335170 (2002-01-01), Orntoft
patent: 6416967 (2002-07-01), Kornblith
patent: 6511806 (2003-01-01), Fruehauf et al.
patent: 6664062 (2003-12-01), Stanton, Jr.
patent: 20020168679 (2002-11-01), Naus et al.
patent: 20020192638 (2002-12-01), Kornblith
patent: 20030096290 (2003-05-01), Fruehauf et al.
patent: 20040023375 (2004-02-01), Kornblith et al.
patent: 20040072722 (2004-04-01), Kornblith et al.
patent: 20040086888 (2004-05-01), Kornblith et al.
patent: WO 9610742 (1996-04-01), None
patent: WO 9802038 (1998-01-01), None
patent: WO 0233117 (2002-04-01), None
patent: WO 2004015065 (2004-02-01), None
patent: WO 2004035833 (2004-04-01), None
Freshney, R.I.,Culture of Animal Cells: A Manual of Basic Technique, 2nd edition, pp. 107, 124-126, 179, 233-234, 290 (1987).
Guo et al., “Direct flourescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports,”Nucleic Acids Research22(24):5456-5465 (1994).
Pfost et al., “A SNPshot: pharmacogenetics and the future of drug therapy,”TIBTECH18:334-338 (Aug., 2000).
Stephens, J.C., “Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics,”Molecular Diagnosis4(4):309-317 (1999).
Tannock et al.,The Basic Science of Oncology, 2nd edition, pp. 247-248, 261-265, 303-306(1992).
Becton-Dickinson Catalog, Anti-Cytokeratin (CAM 5.2) Reagent, pp. 1-11 (1997).
Boehringer Mannheim Catalog, Anti-Cytokeratin AE1/AE3, (1996).
DAKO Catalog, Specification Sheet for Monoclonal Mouse Anti-Human Epithelial Membrane Antigen, pp. 1-2 (1996).
Kornblith, P., “Role of Tissue Culture in Prediction of Malignancy,” Clinical Neurosurgery, vol. 25, pp. 346-376 (1978).
Kornblith, P., et al., “Variations in Response of Human Brain Tumors to BCNU In Vitro,” Journal of Neurosurgery, vol. 48, No. 4, pp. 580-586 (1978).
Kruczynski, A., et al., “Evidence of a Direct Relationship Between the Increase in the In Vitro Passage Number of Human Non-Small-Cell-Lung Cancer Primocultures and their Chemosensitivity,” Anticancer Research, vol. 13, pp. 507-514 (1993).
Nance, K., et al., “Immunocytochemical Panel for the Identification of Malignant Cells in Serous Effusions,” Am J Clin Pathol, vol. 95, pp. 867-874 (1991).
Persons, D., et al., “Interphase Molecular Cytogenetic Analysis of Epitielial Ovarian Carcinomas,” American Journal of Pathology, vol. 142, No. 3, pp. 733-741 (1993).
Pinkus, G., et al., “Optimal Immunoreactivity of Keratin Proteins in Formalin-Fixed, Paraffin-Embedded Tissue Requires Preliminary Trypsinization,” Journal of Histochemistry and Cytochemistry, vol. 33, No. 5, pp. 465-473 (1985).
Raju, G., “The Histological and Immunohistochemical Evidence of Squamous Metaplasia from the Myoepithelial Cells in the Breast,” Histopathology, vol. 17, No. 3, pp. 272-275 (1990).
Singh, H., et al., “Significance of Epithelial Membrane Antigen in the Work-Up of Problematic Serous Effusions,” Diagnostic Cytopathology, vol. 13, No. 1, pp. 3-7 (1995).
Stephens, S., et al., “A Longitudinal Study of γ-Interferon Production by Peripheral Blood Mononuclear Cells from Breast- and Bottle-Fed Infants,” Clin. Exp. Immunol., vol. 65, pp. 396-400 (1986).
Stewart, R., et al., “Glutamate Accumulation By Human Gliomas and Meningiomas in Tissue Culture,” Brain Research, vol. 118, No. 3, pp. 441-452 (1976).
Stoop, J., et al., “Identification of Malignant Cells in Serous Effusions Using a Panel of Monoclonal Antibodies Ber-EP4, MCA-b-12 and EMA,” Cytopathology, vol. 3, pp. 297-302 (1992).
Wiseman, I., “A Modification of Hepatest, using the Terasaki Plate, for the Detection of HbsAg in Blood Donors,” J Clin Pathol, vol. 29, No. 3, pp. 264-266 (1976).
International Search Report for PCT/US01/32540 dated Apr. 18, 2002.
International Search Report for PCT/US97/11595 dated Aug. 17, 1998.
European Search Report for EP 97 93 3267 dated May 3, 2002.
Arnold, J., et al., “Evaluation of Chemopreventive Agents in Different Mechanistic Classes Using a Rat Tracheal Epithelial Cell Culture Transformation Assay,” Cancer Research, vol. 55, pp. 537-543 (1995).
Broadley, C., et al., “A Tissue-Culture Model for the Study of Canine Vocal Fold Fibroblasts,” Laryngoscope, vol. 105, No. 1, pp. 23-27 (1995).
Burczynski, M., et al., “Toxicogenomics-Based Discimination of Toxic Mechanism in HepG2 Human Hepatoma Cells,” Toxicological Sciences, vol. 58, No. 2, pp. 399-415 (2000).
Cilley, R., et al., “Fetal Lung Development: Airway Pressure Enhances the Expression of Developmental Genes,” Journal of Pediatric Surgery, vol. 35, No. 1, pp. 113-119 (2000).
Dietel, M., et al., “In Vitro Prediction of Cytostatic Drug Resistance in Primary Cell Cultures of Solid Malignant Tumours,” Eur J Cancer, vol. 29A, No. 3, pp. 416-420 (1993).
Dudley, D., et al., “A Human Endometrial Explant System: Validation and Potential Applications,” Am J Obstet Gynecol, vol. 167, No. 6, pp. 1774-1780 (1992).
Frykholm, G., et al.,
Gitomer Ralph
Morgan & Lewis & Bockius, LLP
Precision Therapeutics, Inc.
LandOfFree
Method for preparing cell cultures from biological specimens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing cell cultures from biological specimens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing cell cultures from biological specimens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461267